Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIVconsvX
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
HIVconsvX is an investigational T cell–inducing HIV vaccine immunogen designed around conserved regions of the HIV-1 proteome to elicit broad, cross-clade cellular immune responses for HIV prevention and potentially functional cure. It is typically delivered using heterologous prime–boost regimens with viral vectors or nucleic acid platforms and aims to focus T cells on invariant viral epitopes that are less able to escape by mutation. Development has been led by academic and nonprofit HIV vaccine research groups working in collaboration with clinical trial networks.
02
Targets
Gag-Pol (HIV-1 gag-pol polyprotein)
Beyond the preview
Go deeper on HIVconsvX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIVconsvX.